Visão geral da empresa
A clinical-stage biopharmaceutical entity, Immix Biopharma, Inc. specializes in the development of chimeric antigen receptor cell therapy targeting light chain Amyloidosis and immune-mediated diseases within the United States and Australia markets. The company operates within the Healthcare sector, specifically classified under the Biotechnology industry, which implies a focus on high-risk, high-reward research and development phases prior to commercial product launch. Immix Biopharma, Inc. currently maintains a market capitalization of $516.87M, while its annual revenue and total employee count are not disclosed in the available financial data. The market capitalization of $516.87M indicates that the company holds a mid-sized valuation typical of pre-commercial stage biotech firms, where value is derived primarily from intellectual property and pipeline potential rather than current cash generation or sales volume.
Saúde financeira
The company reports a Net Income of $-29,438,612 over the trailing twelve months, accompanied by an EBITDA of $-29,710,668, while revenue figures for the trailing twelve months are not available in the dataset. The substantial negative net income relative to the available EBITDA data suggests a cost structure dominated by research and development expenses or operating inefficiencies that are not yet offset by sales revenue. Free Cash Flow stands at $-13,612,449, indicating that the company is currently consuming cash reserves to fund its operations and development activities rather than generating liquidity. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting a typical scenario for early-stage biotechnology companies where revenue is either non-existent or insufficient to cover the direct costs of sales and operations in the current reporting period. On the liability side, the company holds $100.41M in cash against a debt load of $1.07M, resulting in a Debt to Equity ratio of 1.14 which, while mathematically indicating leverage, must be interpreted cautiously given the context of minimal cash inflows and significant cash on hand. The balance sheet appears to be managed with significant cash liquidity relative to debt obligations, as evidenced by the $100.41M cash position versus the negligible $1.07M debt. Liquidity for short-term obligations is exceptionally strong, as indicated by a Current Ratio of 10.01, which suggests the company possesses more than ten times the liquid assets required to cover its current liabilities. Return on Equity is -55.0% and Return on Assets is -29.3%, revealing that management effectiveness in generating profit from shareholder capital and total assets is currently negative due to the lack of commercial profitability in the current development stage.
Avaliação de valorização
The Trailing Twelve Months P/E Ratio is N/A due to the absence of net income, whereas the Forward P/E is listed as -13.40, implying that future earnings projections are also negative or not yet positive enough to generate a standard valuation multiple. The Price to Book ratio stands at 5.51, indicating that the market values the company at a significant premium of 5.51 times its book value, a common characteristic for biotech firms where intangible assets like patents and clinical data are not fully reflected on the balance sheet. The Price to Sales ratio is N/A because revenue data is unavailable, and the EV/EBITDA stands at -14.04, suggesting that enterprise value is being assessed based on negative earnings multiples typical of pre-revenue or loss-making entities. The stock price has fluctuated between a 52-week high of $11.61 and a 52-week low of $1.34, and without the specific current share price, the exact percentage deviation from these bounds cannot be calculated, but the wide range demonstrates high volatility inherent in the biotechnology sector. The Beta is 0.21, which indicates that the stock's price volatility is significantly lower than that of the broader market, moving in only about 21% of the magnitude of market swings.
Growth & Income
Revenue Growth Year over Year and Earnings Growth Year over Year are both listed as N/A, preventing a direct comparison of earnings growth rates against revenue growth trajectories in the current reporting period. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning the company reinvests all available earnings, including cash reserves, back into its research and development pipeline rather than distributing income to shareholders. Since the company is not a dividend payer, the return for investors is derived entirely from potential capital appreciation rather than income yield. The overall growth and income profile is characterized by a lack of current profitability and income distribution, with the company relying on its substantial cash reserves of $100.41M to fund future development milestones and eventual commercialization of its lead product NXC-201.